Orexo sees very limited exposure to the UK and the British pound

Uppsala, Sweden – June 21, 2016

In response to recent week´s media attention to companies exposure to brexit and GBP Orexo AB (publ) today clarifies that its exposure to the UK and thereby fluctuations in the GBP is very limited. Orexo has no direct income in GBP and has only limited indirect exposure to GBP through the Abstral® partner, Kyowa Kirin’s (former Prostrakan), sales of Abstral in the UK. Royalties from sales of Abstral in the UK amounts to less than 1 percent of Orexo’s annual net revenue and is invoiced by Orexo in euro.

Earlier Orexo has earned one-off Abstral milestone payments in GBP and hence Orexo was historically more exposed to GBP.

Contact Information:
Henrik Juuel, EVP and Chief Financial Officer
Tel: +46 (0)18-780 88 00, E-mail: ir@orexo.com

Lena Wange, IR & Communications Manager
Tel: +46 (0)18-780 88 00, E-mail: ir@orexo.com

About Orexo

Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for maintenance treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo’s share is listed on Nasdaq Stockholm Exchange Mid Cap (STO:ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in Uppsala, Sweden.

For information about Orexo, please visit www.orexo.com. To read more about Zubsolv and opioid dependence, please visit www.zubsolv.com and www.outthemonster.com.

Orexo AB (publ) discloses the information provided herein pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 6:30 a.m. CET on June 21, 2016.

Tags: